SEC Filing Summary: Signal Genetics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Signal Genetics, Inc. on May 16, 2016. The filing serves to disclose a business update and financial results for the first quarter of 2016. The registrant is incorporated in Delaware and maintains its principal executive offices in Carlsbad, California.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing references a press release highlighting "Recent Achievements" and "First Quarter 2016 Financial Results." Specific details regarding material changes compared to the prior period are not present in the 8-K text and must be sourced from the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are detailed in the press release (Exhibit 99.1) rather than the 8-K body. The filing explicitly states that the information contained herein shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific Q1 2016 financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1).
- Review the "Recent Achievements" section of the press release for operational milestones.
- Confirm the company's cash runway and burn rate as disclosed in the full financial update.
- Note that the 8-K text serves only as a conduit for the press release and contains no standalone financial data.